) The Pediatric Oncology Program is comprised of clinical oncologists, surgeons, pathologists, and basic scientists whose interests are related to the diseases of pediatric cancer patients. The overall goal of the Pediatric Oncology Program is to reduce the cancer burden in the pediatric population by its research, education, and clinical programs. To accomplish this goal, the Program has established an integrated group of members, organized in four focus areas: 1) clinical investigations, 2) a clinical and research bone marrow transplant (BMT) program, 3) clinical translational research in leukemias, cytogenetics, and brain tumors, 4) basic science research in DNA tumor viruses, lymphocyte signal transduction, and fusion protein transcription factors created by chromosomal translocations in childhood ALL. The clinical program is an active participant in the Children?s Cancer Group (CCG), and utilizes investigator-initiated protocols developed by Cancer Center members and by the cooperative group whenever possible. Each year approximately 150 new oncology patients are evaluated and/or treated by the oncology staff, and an additional 25-35 children are transplanted on various protocols in the pediatric BMT unit. Protocol development over the past year has included 13 investigator-initiated and 49 CCG protocols, with 153 patients enrolled. Program members are highly interactive with respect to clinical protocol development, translational research, and basic research, as evidenced by the fact that 36% of the 132 publications have intra-or inter-program collaborations despite the fact that most members are new. Future plans will build upon this foundation of interaction in specific areas including: 1)continue integration of Pediatric and Adult programs in Neuro-oncology and BMT; 2)development of a Cancer Genetics Clinic to serve as a focus for new translational and basic research; 3)establishment of a clinical and basic research interest group for studying EBV-related lymphoproliferative disease; 4)increased research in cancer survivorship; and 5)faculty career development for new translational and basic scientists interested in areas related to Pediatric Oncology. This is one of a few approved Pediatric Oncology programs within NCI designated Comprehensive Cancer Centers whose growth has been supported by the UCCC and whose growth is projected to continue in the next five years.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-15
Application #
6589984
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-05-06
Project End
2003-01-31
Budget Start
Budget End
Support Year
15
Fiscal Year
2002
Total Cost
$250,404
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Collins, Keagan P; Jackson, Kristen M; Gustafson, Daniel L (2018) Hydroxychloroquine: A Physiologically-Based Pharmacokinetic Model in the Context of Cancer-Related Autophagy Modulation. J Pharmacol Exp Ther 365:447-459
Villalobos, Victor Manuel; Hall, Francis; Jimeno, Antonio et al. (2018) Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor. Ann Surg Oncol 25:768-775
Montford, John R; Lehman, Allison M B; Bauer, Colin D et al. (2018) Bone marrow-derived cPLA2? contributes to renal fibrosis progression. J Lipid Res 59:380-390
Kogut, Igor; McCarthy, Sandra M; Pavlova, Maryna et al. (2018) High-efficiency RNA-based reprogramming of human primary fibroblasts. Nat Commun 9:745
Goodspeed, Andrew; Jean, Annie; Costello, James C (2018) A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. Eur Urol :
Niemeyer, Brian F; Oko, Lauren M; Medina, Eva M et al. (2018) Host Tumor Suppressor p18INK4c Functions as a Potent Cell-Intrinsic Inhibitor of Murine Gammaherpesvirus 68 Reactivation and Pathogenesis. J Virol 92:
Kiseljak-Vassiliades, Katja; Zhang, Yu; Bagby, Stacey M et al. (2018) Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer 25:437-451
Nellan, Anandani; Rota, Christopher; Majzner, Robbie et al. (2018) Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells. J Immunother Cancer 6:30
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776

Showing the most recent 10 out of 1634 publications